TC BioPharm (Holdings) Ltd Stock Price, News & Analysis

TC BioPharm has appointed Bree Harlin as the new Chief Clinical Officer, effective immediately. With over 20 years of experience in oncology and clinical development, Harlin previously worked at Loxo at Lilly. Her expertise will be crucial as the company aims to expand its clinical trials in the U.S. and submit its first Investigational New Drug (IND) application in the latter half of 2023. TC BioPharm focuses on gamma-delta T cell therapies for cancer treatment and is recognized for its pivotal clinical studies. The company is positioned for growth as it develops its pipeline for various cancer indications.

TC BioPharm, a clinical-stage biotechnology company, will hold a shareholder update call on February 20, 2023, at 10:00 am ET. The meeting will focus on the company's clinical trial plan for allogeneic gamma-delta T cell therapies for cancer, including updates on its ongoing studies for acute myeloid leukemia and future oncology indications. CEO Bryan Kobel and CFO Martin Thorp will lead the call, which will include a Q&A session addressing pre-submitted questions from investors. Interested parties can join via the provided live call numbers or webcast link.

TC Biopharm (NASDAQ: TCBP) has received notice from Nasdaq stating that it has not met the minimum Market Value of Listed Securities (MVLS) of $35 million required for continued listing. The company plans to request a hearing to stay any suspension or delisting, presenting a compliance plan to address the MVLS deficiency. This notification does not immediately affect trading on Nasdaq, and the company’s ADSs and Warrants will continue to be listed while awaiting the panel's decision. Previously, TC Biopharm was given until January 11, 2023, to regain compliance after a July 2022 notice.

TC Biopharm, a clinical-stage biotechnology company, has announced a strategic collaboration with The University of Texas MD Anderson Cancer Center as of January 17, 2023. This partnership aims to enhance understanding of gamma-delta T cells for cancer treatment over a three-year period. The collaboration will harness MD Anderson's clinical trial infrastructure alongside TC Biopharm's gamma-delta T cell oncology pipeline, focusing on preclinical and clinical studies. The initiative is expected to yield insights that will refine future studies and aid in the development of new cancer therapies, particularly in blood cancers and solid tumors.

TC BioPharm (NASDAQ: TCBP) announced significant developments in its clinical pipeline and financial performance. They have dosed the first three patients in a Phase 2b trial for OmnImmune®, a therapy for Acute Myeloid Leukemia (AML), which showed promising response rates in prior studies. Financially, the company reported a net income of £0.5 million ($0.6 million) for the first half of 2022, a turnaround from a £2.6 million loss in 2021. Cash reserves stand at £6.0 million ($7.3 million), bolstered by a recent PIPE financing of £6.0 million in November 2022.

TC BioPharm (Nasdaq: TCBP) has successfully closed a private placement, raising $7.35 million by issuing 1,470,000 American Depositary Shares (ADSs) at a price of $5.00 per ADS. This includes Series A and Series B warrants, both with an exercise price of $5.00. The funds will be used for general working capital. The offering was conducted under Regulation D, targeting accredited investors. TC BioPharm specializes in allogeneic gamma-delta T cell therapies for cancer treatment and is currently engaged in pivotal clinical trials.

TC BioPharm (Nasdaq: TCBP) announced a private placement agreement for 1,470,000 American Depositary Shares (ADSs) and associated warrants, raising an expected $7.35 million. The purchase price is set at $5.00 per ADS, with Series A and B warrants exercisable at the same price. The closing is anticipated on November 30, 2022, subject to customary conditions. Proceeds will support general working capital. The offering is exclusively for accredited investors under Section 4(a)(2) of the Securities Act, and the Company plans to file registration statements with the SEC for resale of the ADSs.

TC Biopharm has initiated the dosing of three patients in its Phase 2b clinical trial of OmnImmune®, targeting Acute Myeloid Leukemia (AML). This trial includes a safety cohort of five patients, with results expected by the end of 2022. Following this, the study will move to open enrollment in January 2023, aiming to enroll around 37 patients, including those with myelodysplastic syndromes. The trial represents a pivotal step in TC Biopharm's strategy to advance its innovative gamma-delta T cell therapies.

TC BioPharm (NASDAQ: TCBP) has appointed a new Scientific Advisory Board (SAB) to enhance its gamma-delta T cell therapies for cancer treatment. The SAB, which includes experts from leading institutions, will focus on advancing clinical trials and establishing strategic partnerships in cell therapy. CEO Bryan Kobel highlighted the potential for growth in gamma-delta platform therapies. The company is already conducting pivotal trials for its OmnImmune® product, targeting acute myeloid leukemia, leveraging its proprietary CryoTC technology to enhance treatment delivery.